Introduction:
Paris-based start-up Klineo SAS has raised €2 million in funding to improve access to clinical trials for cancer patients. The company’s AI-based platform connects patients and doctors directly with relevant trials in less than a minute, democratizing access to new treatments. The funding will help Klineo expand its platform to cover all types of cancer and continue improving the platform medically and technologically. Klineo also plans to expand its platform to other countries and other pathologies such as rare and neurological diseases.
- Klineo SAS has raised €2 million in funding to improve access to clinical trials for cancer patients.
- The company’s AI-based platform connects patients and doctors directly with relevant trials in less than a minute.
- Klineo’s platform allows patients to search for trials and make direct contact with centers where clinical trials are open.
- The funds will enable Klineo to expand its platform to cover all types of cancer in France and eventually in other countries.
- Klineo also plans to expand its platform to other pathologies such as rare and neurological diseases.
Conclusion:
Klineo SAS has raised €2 million in funding to improve equity of access to clinical trials for cancer patients. By connecting patients and doctors directly with relevant trials, the company’s AI-based platform democratizes access to new treatments. The funding will enable Klineo to expand its platform to cover all types of cancer and continue improving the platform both medically and technologically. In the future, Klineo plans to expand its platform to other countries and other pathologies, ensuring that more patients have access to potentially life-saving clinical trials.
